Omalizumab for previously treated chronic spontaneous urticaria

  • Technology appraisal guidance
  • TA339
  • Published: 

History

Expected publication

Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final appraisal determination

Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: appraisal consultation

Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: equality impact assessment: scoping

Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final scope

Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: final matrix

Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: draft scope for consultation (pre-referral) - November 2013

Urticaria (chronic spontaneous, previously treated) - omalizumab [ID707]: provisional matrix (pre-referral) - November 2013